Sanz LRD, Lejeune N, Szymkowicz E, Bonin EAC, Panda R, Sala A, Thibaut A, Huerta-Gutierrez R, Dardenne N, Dikenstein D et al..
2024.
Apomorphine for prolonged disorders of consciousness: a multimodal open-label study.. EClinicalMedicine. 78:102925.
Sanz LRD, Lejeune N, Szymkowicz E, Bonin EAC, Panda R, Sala A, Thibaut A, Huerta-Gutierrez R, Dardenne N, Dikenstein D et al..
2024.
Apomorphine for prolonged disorders of consciousness: a multimodal open-label study.. EClinicalMedicine. 78:102925.
Cheng F, Wang F, Tang J, Zhou Y, Fu Z, Zhang P, Haines JL, Leverenz JB, Gan L, Hu J et al..
2024.
Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease.. Cell Rep Med. 5(2):101379.
Cheng F, Wang F, Tang J, Zhou Y, Fu Z, Zhang P, Haines JL, Leverenz JB, Gan L, Hu J et al..
2024.
Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease.. Cell Rep Med. 5(2):101379.
Marino F, Moreno-López Y, Hollis E.
2024.
Corticospinal Modulation of Precision Movements.. Neurosci Insights. 19:26331055241249497.
Nelson AT, Cicardi MElena, Markandaiah SS, Han JYs, Philp NJ, Welebob E, Haeusler AR, Pasinelli P, Manfredi G, Kawamata H et al..
2024.
Glucose hypometabolism prompts RAN translation and exacerbates C9orf72-related ALS/FTD phenotypes.. EMBO Rep. 25(5):2479-2510.